Continuous Glucose Monitoring in Type 2 Diabetes and Beyond

CGM should be deployed in response to a specific patient problem rather than as a default intervention. Deliberate, equitable deployment of CGM that is aligned with patient goals, clinical context, and system capacity will be necessary to ensure that those most likely to benefit are not left behind, while avoiding overuse in populations for whom benefit remains unproven.

Corresponding Author: Kasia J. Lipska, MD, MHS, Section of Endocrinology and Metabolism, Department of Internal Medicine, Yale School of Medicine, PO Box 208020, New Haven, CT 06520 (kasia.lipska@yale.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.